医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Alteogen Enters into a Non-exclusive License Agreement with a Global Pharmaceutical Company for Use of Its Hybrozyme™ Technology to Enable Subcutaneous Administration of Biologic Products

2019年12月02日 PM10:00
このエントリーをはてなブックマークに追加


 

DAEJEON, South Korea

Alteogen Inc. (KOSDAQ:196170) announced today that it has entered into a non-exclusive global license agreement with a top 10 Global Pharmaceutical Company (GPC) to use ALT-B4, Alteogen’s novel hyaluronidase-derived technology called Hybrozyme™ technology.

ALT-B4 is a proprietary recombinant human hyaluronidase enzyme that enables large-volume subcutaneous administration of biologics that would otherwise be administered as an IV injection.

“We are pleased to enter into our first global agreement for ALT-B4 with an experienced top pharmaceutical company,” said Dr. Soon Jae Park, Chief Executive Officer of Alteogen. “We believe that this deal signifies the potential value of our technology and we look forward to working with the team at the GPC to bring more convenient treatment administration options to patients.”

Under the terms of the agreement, Alteogen has granted worldwide rights for GPC to develop and commercialize multiple products in combination with Hybrozyme™ technology while Alteogen will be responsible for the clinical and commercial supply of ALT-B4 materials. Alteogen will receive an initial payment of USD 13 million and is also eligible to receive additional milestones upon GPC’s achievement of specified development, regulatory and sales milestones, totaling up to USD 1.373 billion.

About ALT-B4

ALT-B4 is Alteogen’s proprietary recombinant human hyaluronidase enzyme developed utilizing the Hybrozyme™ technology. ALT-B4 can enable the large volume subcutaneous administration of drugs that are typically administered as an IV injection. ALT-B4 does this by temporarily hydrolyzing hyaluronan in the extracellular matrix.

About Alteogen Inc.

Alteogen Inc. is a Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics such as Antibody-Drug Conjugates (ADCs), biobetters and biosimilars. Alteogen’s portfolio includes clinical-stage long-acting therapeutic proteins and next-generation ADCs, developed by its proprietary NexPTM-fusion and NexMabTM platform technology, respectively. It also develops Herceptin SC and Eylea biosimilars. The company was founded in 2008 and listed in KOSDAQ (196170.KQ).

View source version on businesswire.com: https://www.businesswire.com/news/home/20191202005348/en/

CONTACT

For Media and Investors

Alteogen Inc.

Arun Swaminathan, Ph.D.

Chief Business Officer and Senior Vice President

phone: +16099378767

arun@alteogen.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 武田和Frazier Healthcare Partners宣布合作成立HilleVax, Inc.以开发临床阶段诺如病毒候选疫苗
  • Astellas and Minovia Therapeutics Announce Strategic Collaboration for Novel Mitochondrial Cell Therapy Programs
  • Sports & Health ShopeeMall & LazMall Store, Crazybadman Extends Discounts Indefinitely to Help Combat Surge in Covid-19 Cases
  • 武田薬品工業: 2021年度第1四半期は堅調な業績を達成、トップライン成長およびパイプラインの持続的な推進を加速
  • Takeda Delivers Solid First Quarter FY2021 Results, Positioning Company to Accelerate Topline Growth and Continued Pipeline Progress